Interparfums (IPAR) Competitors

Interparfums (NASDAQ:IPAR) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap personal products companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Does the media favor IPAR or PBH?

In the previous week, Prestige Consumer Healthcare had 2 more articles in the media than Interparfums. MarketBeat recorded 5 mentions for Prestige Consumer Healthcare and 3 mentions for Interparfums. Prestige Consumer Healthcare's average media sentiment score of 1.28 beat Interparfums' score of 1.19 indicating that Prestige Consumer Healthcare is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Interparfums	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prestige Consumer Healthcare	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, IPAR or PBH?

Interparfums has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

Do institutionals and insiders hold more shares of IPAR or PBH?

55.6% of Interparfums shares are owned by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. 43.9% of Interparfums shares are owned by company insiders. Comparatively, 1.6% of Prestige Consumer Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Is IPAR or PBH more profitable?

Prestige Consumer Healthcare has a net margin of 18.86% compared to Interparfums' net margin of 11.30%. Interparfums' return on equity of 17.62% beat Prestige Consumer Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Interparfums	11.30%	17.62%	11.86%
Prestige Consumer Healthcare	18.86%	12.87%	6.78%

Which has higher earnings & valuation, IPAR or PBH?

Prestige Consumer Healthcare has lower revenue, but higher earnings than Interparfums. Prestige Consumer Healthcare is trading at a lower price-to-earnings ratio than Interparfums, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Interparfums	$1.45B	3.06	$164.36M	$5.14	26.95
Prestige Consumer Healthcare	$1.14B	3.47	$214.60M	$4.29	18.64

Do analysts prefer IPAR or PBH?

Interparfums currently has a consensus target price of $157.60, suggesting a potential upside of 13.78%. Prestige Consumer Healthcare has a consensus target price of $93.33, suggesting a potential upside of 16.70%. Given Prestige Consumer Healthcare's higher possible upside, analysts clearly believe Prestige Consumer Healthcare is more favorable than Interparfums.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Interparfums	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Prestige Consumer Healthcare	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Interparfums beats Prestige Consumer Healthcare on 9 of the 16 factors compared between the two stocks.